Wire Stories

Japanese Patent Holder BWB Files Milestone Intellectual Property Infringement Complaint Against Retail Giant Alibaba Group

SAN FRANCISCO--(BUSINESS WIRE)--In a legal challenge that could have multi-billion-dollar consequences, Tokyo-based BWB Inc. is…

Chinese Taipei Games Market Report – Chinese Taipei Remains a Powerhouse in Semiconductors and Hardware for the Games Industry – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Chinese Taipei Games Market Report" from Niko Partners, Inc. has been added to…

NRS CORPORATION: Establishment of a New Logistics Site in Arizona, U.S.A.

TOKYO--(BUSINESS WIRE)--NRS CORPORATION is pleased to announce the opening of a new comprehensive logistics site…

Hanshow, Microsoft, Intel, and E Ink Jointly Release Industry White Paper Exploring Green Digitalization in the Future of Retail

BEIJING--(BUSINESS WIRE)--#DigitalRetail--Hanshow, Microsoft, Intel, and E Ink have issued a joint white paper on Green…

Bloom Energy and SK ecoplant Announce 500 MW Sales Agreement Strengthening Existing Partnership

SAN JOSE, Calif. & SEOUL, South Korea--(BUSINESS WIRE)--Bloom Energy (NYSE: BE) and SK ecoplant, an…

Stronghold Enters Into $15 Million Private Placement

Provides Panther Creek Plant Update NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Stronghold Digital…

OliX Pharmaceuticals Receives HREC Approval to Initiate Phase 1 Clinical Trial of NASH and Obesity Drug

SUWON, South Korea--(BUSINESS WIRE)--#AMD--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today…

Japan Video Games Market Report 2023- In-Depth Analysis of Japan’s Robust Gaming Market Unveiled – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Japan Games Market Report" report from Niko Partners, Inc. has been added to…

2024 to Bring “Reputational Security” into Focus – Crisis Management Centre

KUALA LUMPUR, Malaysia--(BUSINESS WIRE)--#CrisisCommunication--The Crisis Management Centre foresees that 2024 will carry with it increased…

FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)

U.S. label update includes superior progression-free survival results from the Phase 3 ALPINE head-to-head trial…